Medical devices, healthcare technology and the business of care
510(k) clearance · K261729

EnSite X EP System

ABBOTT MEDICAL · Decision date Sep 17, 2026

MEDTECHLEDGER EXPLANATIONK261729

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 17, 2026 for K261729, a Traditional 510(k) submitted by Abbott Medical of St. Paul, Minnesota, and received May 26, 2026. The subject is the EnSite™ X EP System, a Class II programmable diagnostic computer under 21 CFR 870.1425, product code DQK, in the Cardiovascular specialty. SESE is a clearance to market, not a premarket approval.

The 510(k) summary states the cleared configuration is EnSite™ X EP System version 6.1 with EnSite™ AI Geo Software Licenses installed, compared against predicate EnSite™ X v6.0 (K260212). The stated software revision is the introduction of the EnSite™ AI Geo Software License; the summary reports the same intended use and indications as the predicate and that design verification and validation met acceptance criteria. The summary does not quantify the AI Geo change or provide clinical performance data, so any effect on mapping or procedural outcomes remains unestablished here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Sep 17, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261729
Regulatory pathway
510(k) premarket notification
Product code
DQK
Decision code
SESE
Decision date
Sep 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Computer, Diagnostic, Programmable.

Product code
DQK
FDA device class
2

FDA decision timeline

  1. K261729 received

    Application receipt date recorded by FDA.

  2. K261729 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DQK

Product / regulatory recordCompanyPathwayDecision dateSource
Merge Healthcare Incorporated510(k) clearanceNov 5, 2026FDA
Catheter Precision, Inc.510(k) clearanceOct 30, 2026FDA
PulseAI, Ltd.510(k) clearanceOct 27, 2026FDA
Rhythm AI, Ltd.510(k) clearanceOct 23, 2026FDA
Centerline Biomedical510(k) clearanceOct 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
St. Paul, MN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records